These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34694198)

  • 1. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.
    Falkenius J; Keskitalo J; Kanter L; Johansson H; Höiom V; Hansson J; Egyhazi Brage S
    Acta Oncol; 2022 Jan; 61(1):14-21. PubMed ID: 34694198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
    BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
    de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
    Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.
    Chatziioannou E; Roßner J; Aung TN; Rimm DL; Niessner H; Keim U; Serna-Higuita LM; Bonzheim I; Kuhn Cuellar L; Westphal D; Steininger J; Meier F; Pop OT; Forchhammer S; Flatz L; Eigentler T; Garbe C; Röcken M; Amaral T; Sinnberg T
    EBioMedicine; 2023 Jul; 93():104644. PubMed ID: 37295047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
    Tas F; Erturk K
    Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma.
    Paver EC; Ahmed T; Burke H; Saw RPM; Stretch JR; Spillane AJ; Shannon KF; Vergara IA; Elder DE; Lo SN; Thompson JF; Scolyer RA
    JAMA Dermatol; 2023 Dec; 159(12):1359-1367. PubMed ID: 37910123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study.
    Eriksson H; Frohm-Nilsson M; Järås J; Kanter-Lewensohn L; Kjellman P; Månsson-Brahme E; Vassilaki I; Hansson J
    Br J Dermatol; 2015 Jan; 172(1):175-86. PubMed ID: 24910143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
    Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
    Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
    Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
    Iacono D; Cinausero M; Gerratana L; Angione V; Scott CA; De Maglio G; Pizzolitto S; Di Loreto C; Puglisi F; Fasola G; Minisini AM
    Melanoma Res; 2018 Dec; 28(6):547-554. PubMed ID: 29794562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
    Eriksson H; Lyth J; Andersson TM
    Int J Cancer; 2016 Jun; 138(12):2829-36. PubMed ID: 26815934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.
    Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1468-1474. PubMed ID: 28419674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of primary cutaneous melanoma.
    Winnepenninckx V; Van den Oord JJ
    Verh K Acad Geneeskd Belg; 2007; 69(1):23-45. PubMed ID: 17427873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
    Eggermont AM; Spatz A; Lazar V; Robert C
    Curr Opin Oncol; 2012 Mar; 24(2):137-40. PubMed ID: 22234255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.
    Rubió-Casadevall J; Carbó-Bagué A; Puigdemont M; Osca-Gelis G; Oliveras G; Vilar-Coromina N; Ferrer-Fabrega B; Urban A; Llobet-Roma M; Martín-Romero F; Perez-Bueno F; Marcos-Gragera R
    Eur J Dermatol; 2021 Oct; 31(5):616-622. PubMed ID: 34789445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.